What Belite Bio, Inc does.

We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have significant unmet medical need such as (i) Geographic Atrophy (GA), the late atrophic (“dry”) form of age-related macular degeneration (AMD), and (ii) Stargardt disease type 1 (STGD1). Both GA and STGD1 cause progressive loss of vision leading to permanent blindness in almost all cases. In addition to our lead product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, our drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Our lead product candidate, tinlarebant (a/k/a LBS-008), is an orally administered, once-a-day tablet intended as an early intervention for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. Currently, there are no FDA approved treatments for STGD1 and no approved orally administered treatments for GA. Therefore, if approved, tinlarebant would be a novel oral therapeutic addressing an unmet medical need in both STGD1 and GA.

Revenue and profit, by fiscal year.

More on BLTE.

• Belite Bio, Inc summary
• Belite Bio, Inc financial statements
• Belite Bio, Inc key metrics
• Belite Bio, Inc health scores and style box
• Belite Bio, Inc earnings
• Belite Bio, Inc dividends
• Belite Bio, Inc valuation
• Belite Bio, Inc ownership and insiders
• Belite Bio, Inc peers

Figures from Belite Bio, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.